Clinical Trial Results: Lymphocytic Leukemia, Chronic

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Combination with a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in Combination Chemotherapy in Patients with B-Cell Chronic Lymphocytic Leukemia

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
CHAIROS study A Study of MabThera (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy

Product Name: MabThera/Rituxan [rituximab]
Date of Report: 5/2/2007
Phase: II
An open, uncontrolled, monocentric clinical trial to evaluate activity and toxicity of rituximab in chronic lymphocytic leukemia (CLL) patients responsive to first line therapy with chlorambucil (CB) and prednisone (PDN).

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.

Product Name: MabThera/Rituxan [rituxmab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.